On 17 September, BYK issued a notice on the change of authorised distributors: it terminated the authorisation of Hualing Coatings (a long-standing North-China agent) and, from 1 October, hands the North-China territory (nine provinces) to Dongyang Chemicals (Tianjin).

The trade's first reaction was three words: retreat.

If you were a foreign company wanting out of China, would you pour money in while pulling out?

Over the past 12 months BYK has: expanded its Guangzhou lab (150 → 280 m²), built a mini-plant in Shanghai (500 t/yr capacity), opened an official flagship store on 1688, and — in its annual report — reported Asia as the only region with positive operating growth. Group revenue was €1.2891 bn (−4% YoY), yet Asia was the sole bright spot; ALTANA's China revenue was €562 m (+1%, or +5% on an operating basis).

Would you expand labs, build plants and open an online store, and then announce an exit?

No.

In plain terms, BYK is not re-deciding whether to stay in China — it is re-deciding how to sell, and who sells. That distinction is night and day for anyone in this business.

I. Where has the moat in coatings additives moved?

For many in coatings additives, the first instinct is "sell product": cheap, complete, fast.

But ask yourself — does the customer buy a kilogram of additive, or "whether this kilogram makes their product run"?

Dosage is low, yet the impact on formulation performance is high. Wetting/dispersing, defoaming, levelling, rheology, surface control — these typically must be matched against resin, pigment/filler, solvent and the application system.

In plain words: a coatings additive is not a bottle you buy and forget. It is part of formulation engineering.

So whoever answers fastest — "does this kilogram make my product run?" — wins the order. And "fastest answer" rests on application labs, local technicians and formulation databases.

Look at what BYK is expanding — application labs and a mini-plant. Not ad budgets, not trade shows, but the physical carriers of technical service.

The moat in this industry was never the formulation patent itself. It is technical-service capability.

Foreign suppliers spent decades teaching this. Yet many domestic players still operate on a "sell product" logic — assuming cheap and well-stocked wins.

That is the costliest misjudgement of the past 20 years. Those still acting like traders are fighting on a track whose moat has already moved — like grinding levels in a dungeon after the boss has moved to the next floor.

II. The middle layer is being compressed — a gap is opening

BYK's move lays its channel structure bare.

Before: five regional agents — Hualing, Dongyang, Changzhou Liansheng, Wuhan Fuwei, Xi'an Baosheng.

Now: Dongyang alone covers South-West + South + North China — roughly half the map. Lingwei Technology already exited the BYK agency in 2023 — "profit margins kept shrinking".

The middle layer is being compressed.

What is the flip side of that gap? Imagine you are a coatings plant buying 50–500 t/yr. How would you feel?

  • BYK direct? It serves the big accounts; you are not on the list.
  • Regional distributor? Now consolidated, service radius shrinking.
  • 1688 flagship? That sells long-tail, not service.

You are caught in the middle.

This middle layer used to be a market "too small to bother with". Now it is a market "actively abandoned".

That is why I call this gap the clearest window in fine chemicals for the next 3–5 years — not because it is large, but because it is opening and nobody is claiming it.

III. What Dongyang Chemicals got right

A word on Dongyang Chemicals.

This Tianjin trading firm, founded in 1982, became a BYK general agent in 1995 and has held the seat ever since. Why?

It sells more than BYK: BYK additives, Evonik matting agents and fumed silica, Allnex resins, Vibrantz pigments — multi-brand speciality chemicals, fully assembled, plus technical service.

Neither alone is rare; together they are scarce. It does not sell any single brand — it sells the ability to "equip one mid-sized coatings plant with everything its formulation needs, in a single visit".

BYK needs that partner, so it shrank from five agents to three and amplified the strongest.

The lesson for founders: if you cannot be a "Dongyang Chemicals", do not be a regional agent — that is a dead end. What you can be is the layer Dongyang does not reach, served at a speed BYK-direct cannot match.

In short, Dongyang's moat is not stockpiling — it is assembly + technical service. Worth pondering for anyone building a channel.

IV. Three paths — not parallel, but sequential

After BYK, the future is not "another trader".

Path A — Technical compounding service provider

Stop selling standard products; sell "formulation + technical service + 24-hour response". The customer throws a formulation problem at you; you return a solution, charging a service fee or a product premium.

Benchmark logic: BYK itself is moving this way — direct team + application lab + mini-plant — essentially turning "sell product" into "sell technical service". You do not need BYK's scale; use the same model to attack the mid-sized customers BYK-direct cannot cover and distributors serve poorly.

  • Startup capital: ¥300k–800k (lab/bench equipment + 1 technical assistant + 6 months runway)
  • Cash cycle: 2–4 months (service fee can be collected upfront; product billed later)
  • Main failure mode: BYK / Sika direct teams poach your big accounts. — But that is good; it means you were right.

Path B — Niche-category factory-direct

Pick a small category the big foreign brands disdain, build modest capacity (200–500 t/yr), sell direct from the plant, technology-driven.

Benchmark logic: BYK's Shanghai mini-plant at 500 t/yr, small-batch multi-variety, already proves small-scale flexible manufacturing is a viable business model.

  • Startup capital: ¥1m–3m (EIA / safety / fire / discharge permits + equipment)
  • Cash cycle: 6–12 months
  • Main failure mode: capacity built but unsold; or crushed by a larger player.
  • Note: not for early-stage founders. EIA/safety cycles alone run 12–18 months; with ramp-up, year one is basically profitless.

Path C — Technical export service partner

Become the "technical go-to-market partner" for Chinese fine-chemical manufacturers — you own overseas technical liaison, formulation adaptation and trial validation; the manufacturer owns production. Charge a liaison fee + sales commission.

Benchmark logic: BYK entered China with "foreign technology + Chinese channel". Reverse it: "Chinese technology + your overseas channel". Chinese fine-chemical R&D now approaches international standards, but lacks someone who can explain the technology clearly to foreigners.

  • Startup capital: ¥100k–300k (travel + sampling + trade shows)
  • Cash cycle: 1–3 months
  • Main failure mode: bypassed by the manufacturer going direct; or the customer intercepted by a local supplier.

V. Five iron rules, all earned the hard way

On the road of fine chemicals, a few lines were written, crossed out, and written again:

Rule 1: Sell service before product. Technical service needs no factory — only you. Collect the service fee first to validate willingness to pay, then talk productisation.

Rule 2: Do not build factories; avoid heavy assets. At every early decision ask "can this be outsourced?". Plant, equipment, warehouse, team are cost centres; only your formulation ability, customer network and AI toolchain are assets.

Rule 3: The first customer beats the first product. Spend six months polishing a product and you may find no buyer. Spend six weeks finding someone willing to pay, and they tell you what the product should be — a hundred times better than imagining it in the lab for six months.

Rule 4: Your biggest "unfair advantage" is non-replicable relationships. Not everyone has face-to-face contacts at major accounts, or collaboration experience with them. That network is worth more than any patent because it cannot be copied. Use it well, but do not exhaust it.

Rule 5: AI is your lever, not your product. AI's value is not the product itself but amplifying the scale of your technical service. One person serves 5 clients; with an AI toolchain, 50. Use it to cover team gaps; do not turn it into a new business.

VI. Why now

This window may not return.

Four signals stack together:

Signal 1: BYK's channel consolidation is releasing a batch of neglected mid-sized customers. After Hualing's exit, nine provinces lack short-term technical-service support — not a crisis, but an opportunity window.

Signal 2: Foreign suppliers are validating the "technical-service model" to the end. BYK's Guangzhou lab, Shanghai mini-plant and 1688 store all say the same thing — technical service is the new normal. You do not need to invent it; follow.

Signal 3: Chinese fine-chemical manufacturers now approach international capability, but lack someone to tell the story outward. Overseas customers are not short of supply; they lack a "technical partner" who understands their formulation system.

Signal 4: AI has cut the marginal cost of technical service by an order of magnitude. A technical advisor serving 10 clients a year was once a ceiling; with the right toolchain, 50. That lever did not exist ten years ago.

VII. Closing

On BYK swapping agents, the trade's first reaction was "foreign retreat", the second "channel consolidation".

But what practitioners should remember is the third layer:

The moat has migrated from "formulation" to "technical service", and from "product" to "solution".

Those who do not keep up will be covered by old players like BYK with their direct teams.

Those who do will use the three axes — "technical service + Chinese technology + AI leverage" — to attack the market no foreign direct team or domestic trader can reach.

Stop staring at that stone. Count how many soldiers you actually have. An asset you cannot defend is not an asset — it is a death knell.

One last question: what signal do you read in BYK's move — "foreign retreat", "channel consolidation", or something else? Share in the comments.